PALO ALTO, Calif.--(BUSINESS WIRE)--twoXAR, Inc., a company pioneering digital approaches to drug discovery, today announced that the Stanford University-backed StartX Med program has selected the company for its Summer 2015 Accelerator Session.
Founded in 2014, twoXAR (pronounced: “two-czar”) is transforming how large biological datasets are harnessed to accelerate the identification and validation of new medicines. The company’s DUMA™ platform rapidly evaluates massive public and proprietary datasets to identify and rank high probability drug-disease matches. These drug-disease matches can then be used accelerate the process of repurposing existing drugs as well as identifying novel drug candidates for further clinical testing.
“twoXAR has made remarkable progress bringing passion and ideas into an established industry and we are pleased to welcome them to the StartX Med community,” said Andrew Lee, co-founder of StartX Med and Stem Cell Theranostics. “With their passion and expertise, we are sure they will quickly achieve exciting new milestones while working with StartX.”
StartX Med is a medical and life science vertical within the StartX accelerator that only accepts approximately 10 percent of the companies who apply. StartX Med has created an ecosystem of Stanford’s top medical entrepreneurs and built an organized system of mentors, educational content, and infrastructural resources such as SBIR grant support, FDA and HIPAA consulting, and IP licensing support to facilitate the advancement of breakthrough medical innovations. Mentors provide teams guidance and advice in technology development and business management. Supporters of StartX include Stanford University, Stanford Health Care, Steelcase, and Johnson & Johnson Innovation, among others. StartX requires no fees and takes zero equity in participating companies. StartX also provides participants access to the Stanford-StartX Fund which invests 10 percent of a fundraising the round when a company meets a set of objective criteria.
“twoXAR is dedicated to helping realize the tremendous investments that have been made in generating biological and medical data by bringing them together in a novel way that radically reduces the time it takes to discover life-enhancing and life-saving treatments for patients,” said Andrew A. Radin, co-founder and Chief Executive Officer of twoXAR. “We are pleased to have been chosen by the StartX Med team to participate in this summer’s program and look forward to working with them to accelerate our entrance into the commercial market.”
twoXAR is initially focused on identifying more effective treatments for neurological and metabolic diseases and has identified a number of candidates that they are actively taking through preclinical studies in collaboration with leading patient advocacy, academic research and biopharmaceutical organizations.
For more information please visit, www.twoXAR.com.
Founded in 2014 by two entrepreneurs named Andrew Radin, twoXAR is transforming how large biological datasets are harnessed to accelerate the identification and validation of new medicines. Based in Palo Alto, California, the twoXAR team includes experts in drug discovery, biomedical informatics, computational biology, data science, software development and preclinical validation. For more information please visit, www.twoXAR.com.